Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients

Journal of Infection

Volumn 69, Issue 5, 2014, Pages 500-506

  Martín Gandul, Cecilia ^a,b   Pérez Romero, Pilar ^a,b   González Roncero, Francisco M ^c   Berdaguer, Soledad ^d   Gómez, Miguel A ^e   Lage, Ernesto ^a   Sánchez, Magdalena ^a,b   Cisneros, José M ^a,b   Cordero, Elisa ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Unit of Nephrology and Urology   (Spain)

^d Service of Clinical Pharmacology   (Spain)

^e Hepatobiliary and Pancreatic Surgery and Hepatic Transplant Unit   (Spain)

Author keywords

Cytomegalovirus; Neutropenia; Preemptive therapy; Solid organ transplant; Valganciclovir

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INFECTION RISK; KIDNEY GRAFT; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPENIA; OBSERVATIONAL STUDY; PREEMPTIVE THERAPY; TREATMENT DURATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; CHEMICALLY INDUCED; COMPLICATION; CYTOMEGALOVIRUS INFECTIONS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; RISK FACTOR;

ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEUTROPENIA; RISK FACTORS; TRANSPLANT RECIPIENTS;

EID: 84908543010     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.07.001     Document Type: Article

References (27)

1. Eid A.J., Razonable R.R. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010, 70:965-981.
2. Torres-Madriz G., Boucher H.W. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2008, 47(5):702-711.
3. Wiltshire H., Paya C.V., Pescovitz M.D., Humar A., Dominguez E., Washburn K., et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005, 79(11):1477-1483.
4. Strippoli G.F., Hodson E.M., Jones C.J., Craig J.C. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006, 81(2):139-145.
5. Díaz-Pedroche C., Lumbreras C., San Juan R., Folgueira D., Andrés A., Delgado J., et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006, 82(1):30-35.
6. Bodey G.P., Buckley M., Sathe Y.S., Freireich E.J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukaemia. Ann Intern Med 1966, 64(2):328-340.
7. BenMarzouk-Hidalgo O.J., Cordero E., Martín-Peña A., García-Prado E., Genitl M.A., Gómez-Bravo M.A., et al. Prevention of cytomegalovirus diseases using preemptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection. Antivir Ther 2009, 14(5):641-647.
8. Martín-Gandul C., Pérez-Romero P., Sánchez M., Bernal G., Suárez G., Sobrino M., et al. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol 2013, 56(1):13-18.
9. de la Torre-Cisneros J., Fariñas M.C., Castón J.J., Aguado J.M., Cantisán S., Carratalá J., et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011, 29(10):735-758.
10. Common Terminology Criteria for Adverse Events version 4.0 (CTCAE). [last accessed 28.09.11]. http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf.
11. Valcyte® data sheet. [last accessed 30.09.11]. http://www.medsafe.govt.nz/profs/datasheet/v/Valcytetab.pdf.
12. Hodson E.M., Jones C.A., Webster A.C., Strippoli G.F.M., Barclay P.G., Kable K., et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005, 365(9477):2105-2115.
13. Wiltshire H., Hirankarn S., Farrell C., Paya C., Pescovitz M.D., Humar A., et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005, 44(5):495-507.
14. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4(4):611-620.
15. Kalil A.C., Freifeld A.G., Lyden E.R., Stoner J.A. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One 2009, 4(5):5512.
16. Len O., Gavaldà J., Aguado J.M., Borrell N., Cervera C., Cisneros J.M., et al. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis 2008, 46(1):20-27.
17. Bhat V., McIntyre M., Meyers T. Efficacy and safety of a lower-dose valganciclovir (valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients. P & T 2010, 35(12):676-679.
18. Kalil A.C., Mindru C., Florescu D.F. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis 2011, 52(3):313-321.
19. Humar A., Lebranchu Y., Vincenti F., Blumberg E.A., Punch J.D., Limaye A.P., et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transpl 2010, 10:1228-1237.
20. da Cunha-Bang C., Iversen M., Mortensen S.A., Rasmussen A., Sengeløv H., Sørensen S.S., et al. Regarding: Humar etal. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transpl 2010: 10: 1228. Am J Transplant 2011, 11(2):408.
21. Welker H., Farhan M., Humar A., Washington C. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. Transplantation 2010, 90(12):1414-1419.
22. Caldés A., Gil-Vernet S., Armendariz Y., Colom H., Pou L., Niubó J., et al. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics. Transpl Infect Dis 2010, 12(3):204-212.
23. Zafrani L., Truffaut L., Kreis H., Etienne D., Rafat C., Lechaton S., et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transpl 2009, 9(8):1816-1825.
24. Preiksaitis J.K., Brennan D.C., Fishman J., Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transpl 2005, 5(2):218-227.
25. Fellay J., Venetz J.-P., Aubert J.-D., Seydoux C., Pascual M., Meylan P.R.A. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Transplant Proc 2005, 37(2):949-951.
26. Fellay J., Venetz J.-P., Pascual M., Aubert J.-D., Seudoux C., Meylan P.R.A. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Am J Transpl 2005, 5(7):1781-1782.
27. Park S.Y., Kim Y.H., Han D.J., Park S.K., Park J.S., Sung H., et al. Efficacy of strategy for discontinuing pre-emptive ganciclovir therapy after a negative cytomegalovirus antigenaemia test result in seropositive kidney transplant recipients. J Antimicrob Chemother 2013, 68(5):1209-1211.